Search
Abivertinib
go.drugbank.com/drugs/DB15327Investigational[L17388] Abivertinib's potential to depress cytokine production has led to its investigation in the treatment of hospitalized patients with moderate-to-severe COVID-19. … The study is expected to be completed in March 2021.[L17398]
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline
go.drugbank.com/drugs/DB08550ExperimentalPotent reversible inhibitor of phenylethanolamine N-methyltransferase.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeFenthion
go.drugbank.com/drugs/DB11412ExperimentalVet approvedFenthion is listed as a restricted use compound by the United States Environmental Protection Agency due to its potential to cause cholinesterase inhibition in humans and animals. … Its mode of action is explained by cholinesterase enzyme inhibition, which is similar to other organophosphates.
Synonyms: O,O-Dimethyl O-4-methylthio-m-tolyl phosphorothioate, O,O-Dimethyl O-[3-methyl-4-(methylsulfanyl)phenyl] thiophosphateItolizumab
go.drugbank.com/drugs/DB16207InvestigationalItolizumab is under investigation in clinical trial NCT04605926 (A Study to Evaluate the Efficacy and Safety of Itolizumab in Subjects Hospitalized With COVID-19).
VIT-100
go.drugbank.com/drugs/DB05865ExperimentalIn preclinical studies, companyl has shown that VIT-100 inhibits the growth of cells taken from multiple keloid biopsies as compared to the same keloidal cells treated with a control.
Fontolizumab
go.drugbank.com/drugs/DB05111InvestigationalFontolizumab (marketed under the trade name HuZAF™) is a humanized monoclonal antibody which is used as an immunosuppressive drug to treat Crohn's disease.
D-norleucine
go.drugbank.com/drugs/DB04419ExperimentalAn unnatural amino acid that is used experimentally to study protein structure and function. It is structurally similar to METHIONINE, however it does not contain SULFUR.
1,4-Dithiothreitol
go.drugbank.com/drugs/DB04447ExperimentalA reagent commonly used in biochemical studies as a protective agent to prevent the oxidation of SH (thiol) groups and for reducing disulphides to dithiols. [PubChem]
GO-203-2C
go.drugbank.com/drugs/DB15008InvestigationalGO-203-2C is under investigation in clinical trial NCT02204085 (A Phase I/II Trial of the MUC1 Inhibitor, GO-203-2C in Patients With Relapsed or Refractory Acute Myeloid Leukemia).
AGS-005
go.drugbank.com/drugs/DB05741ExperimentalAGS-005 is a personalized dendritic cell-based immunotherapy, with optimized immune response characteristics, that is designed to stimulate the patient's immune system to target and destroy the patient's